BAG3 is a co-chaperone of the heat shock protein (Hsp) 70, is expressed in many cell types upon cell stress, however, its expression is constitutive in many tumours. We and others have previously shown that in neoplastic cells BAG3 exerts an antiapoptotic function thus favoring tumour progression. As a consequence we have proposed BAG3 as a target of antineoplastic therapies. Here we identify a novel role for BAG3 in regulation of neo-angiogenesis and show that its downregulation results in reduced angiogenesis therefore expanding the role of BAG3 as a therapeutical target. In brief we show that BAG3 is expressed in endothelial cells and is essential for the interaction between ERK and its phosphatase DUSP6, as a consequence its removal results in reduced binding of DUSP6 to ERK and sustained ERK phosphorylation that in turn determines increased levels of p21 and p15 and cell-cycle arrest in the G1 phase.
INTRODUCTION
BAG3 protein, a co-chaperone of the heat shock protein (Hsp) 70, 1 --2 is expressed in many cell types upon cell stress, mainly through the binding of the heat shock factor 1 to its promoter. 3 In normal cells, bag3 constitutive expression is limited at very few cell types, including skeletal and heart myocytes. 4 On the other hand, bag3 expression is constitutive in some neoplastic cell types, in which BAG3 protein appears to exert an anti-apoptotic role. From the first evidence of BAG3-mediated survival in B-CLLs, 5 a number of reports confirmed the anti-apoptotic activity of the protein in tumours of different compartments. 2,5 --20 Indeed, BAG3 down-modulation enhances apoptosis in leukaemia, 9 melanoma, 19 osteosarcoma, 19 glioblastoma 18, 20 and thyroid carcinoma cells, 14 whereas its overexpression protects the cells from pro-apoptotic inputs (serum deprivation, oxidants and drugs). 19 Two principal elements contribute to the role of BAG3 in a vast range of tumours: bag3 induction by heat shock factor 1, 3 a transcription factor activated in many cancer types 21 and BAG3 ability to sustain NF-kB activity. 22 Indeed, it has recently been shown that BAG3 modulates the Hsp70-mediated delivery of IKKg to proteasome, thereby enhancing the activation of NF-kB factors. 19 It is likely that the Hsp70-mediated delivery of other anti-apoptotic proteins to proteasome could be influenced by BAG3 as well. 23 In addition, BAG3 can also bind to other proteins via its proline-rich (PXXP) or WW domains, 24 possibly resulting in a modulation of their activity. Because of its multifaceted ability to complex with many proteins, BAG3 can regulate factors that are particularly relevant in the context of specific tumour types, such as BAX in glioblastoma cells. 18 Overall, studies on BAG3 expression and activity delineate a complex picture of BAG3 involvement in physiological and pathological processes. 25 The pleiotropic functions attributed to BAG3 probably reflect the adaptor nature of this multidomain (BAG, WW and PXXP) protein and its ability to assemble scaffolding complexes that participate in more than one signal transduction pathway.
In this paper we report that BAG3 is expressed in human umbilical vein endothelial cells (HUVECs) and that its downregulation results in a cell-cycle arrest in the G1 phase, though an enhanced phosphorylation of ERK1/2 that in turn determines increased expression of the cell-cycle inhibitors p21 and p15. BAG3 exerts its effect on ERK by allowing its interaction with DUSP6, a phosphatase that dephosphorylates ERK. We also show that through this mechanism BAG3 regulates tumour neoangiogenesis and therefore is a novel target for anti-angiogenic therapies.
RESULTS

BAG3 silencing inhibits tumour growth and neo-angiogenesis
We have previously shown that downregulation of BAG3 results in reduction of tumour growth. 18, 19 Indeed as shown in Figure 1a intratumoral treatment with bag3 small interfering (si) RNA-Ad resulted in inhibiting tumour growth of A375 melanoma xenografts, whereas treatment with control virus had no effect. Unexpectedly immune-histochemical analysis of resulting tumours (Figure 1b) , using HMB-45 as a marker of melanoma cells, shows an equal distribution of BAG3 signal both in bag3siRNA-Adtreated tumours and controls without any remarkable difference. Conversely, high levels of BAG3 expression were observed in the vessels of null adenovirus (AdNull) and negative control tumours, whereas very low levels or absent BAG3 expression were detected in vessels of bag3siRNA-Ad-treated tumours. Evaluation of the number of vessels stained using anti-von Willebrand Factor antibody (Figure 1c ), in the same tumour samples, shows a decreased number of blood vessels in bag3siRNA-Ad-treated tumours compared with AdNull and negative controls. These results strongly suggested that BAG3 influenced tumour associated neo-angiogenesis.
To confirm that BAG3 is indeed required for in vivo neoangiogenesis, we used Direct In Vivo Angiogenesis Assay, a well-established model of angiogenesis. 26 --28 This consists of subcutaneous implantation of semiclosed silicone cylinders (angioreactors), filled with extracellular matrix premixed with angiogenic factors, into the nude mice. Invasion by murine endothelial cells was evident in control angioreactors and in angioreactors in which a control adenoviral vector (AdNull) had been added; conversely, endothelial cell presence was hardly detectable in angioreactors in which we added an adenoviral construct carrying bag3siRNA (bag3siRNA-Ad) (Figure 1d ). Successive analysis of the number of FITC-lectin-positive cells showed a significant decrease of endothelial cells in bag3siRNA-Ad-treated angioreactors (Figure 1e) . Altogether these data demonstrate that BAG3 is involved in tumour neo-angiogenesis and that its loss results in reduced growth of blood vessels.
BAG3 down-modulation in HUVECs results in a G1 block To further investigate the molecular mechanisms underlying BAG3 role in angiogenesis we studied the effects of its silencing in HUVECs in vitro. It is of note that in contrast with adult endothelial cells, HUVECs express high amounts of BAG3 protein. Downregulation of BAG3 by specific siRNA (Figure 2a and b) results in a strong inhibition of their growth whereas a non-targeted (NT) siRNA used as control had no effect. Interestingly this is a true cytostatic effect as no increase of dead cells was detected by ERK1/2 phosphorylation, p15 and p21 levels are enhanced in bag3-silenced cells To further investigate the molecular mechanisms underlying the role of BAG3 in cell-cycle regulation in these cells we analysed the effect of BAG3 silencing on levels and/or phosphorylation of some of the main players involved in cell-cycle progression, particularly those involved in the progression at the G1/S check point. Figure 2d shows that reduced BAG3 levels result in increased ERK1/2 phosphorylation and reduction of phospho-Rb (retinoblastoma) levels. These changes parallel the reduction of BAG3 levels. Although sustained activation of ERK is required for cellcycle progression through the G1 to S phase, high levels of ERK phosphorylation are known to result in block in the G1 phase of the cell cycle rather than progression to the S phase. 29 --31 This is because of failure to phosphorylate Rb by the cyclin D Cdk4/6 complex first and by the Cyclin E Cdk2 complex at the end of G1. p21 upregulation precedes that of p15 and explains the initial G1 block, further increase in p21 levels as well as induction of p15 ( Figure 3a and b) results in more cells being arrested in G1 (Figure 2c ). Interestingly upon BAG3 silencing, cyclin D1 levels are reduced despite the high levels of pERK1/2 providing an additional mechanism through which BAG3 silencing can lead to reduced Rb phosphorylation and consequent G1 block.
To confirm that what we are observing in vitro also occurs in vivo in our animal model we stained tumour samples from control animals or animal treated with bag3siRNA-Ad or a control virus. As shown in Figure 3e treatment with bag3siRNA-Ad results in reduced BAG3 expression that is accompanied by increased expression of pERK1/2 and p21.
These data clearly show that BAG3 is essential for G1/S progression and its loss results in G1 arrest mediated by the ERK1/2 pathway. BAG3 protein interacts with ERK1/2 kinase and its phosphatase DUSP6 One possible mechanism through which BAG3 can regulate ERK1/2 phosphorylation is by recruiting phosphatases that can dephosphorylate them. One of the main phosphatases that regulate ERK1/2 phosphorylation levels is DUSP6/MKP-3.
36 -- 38 We therefore investigated whether BAG3 could affect the interaction between these proteins. To this end, we immunoprecipitated BAG3 from HUVEC lysates and analysed the immunoprecipitate with anti-ERK 1/2 and anti-DUSP6 antibodies by western blotting. Both proteins were co-immunoprecipitated with BAG3 whereas none was pulled down by control IgGs (Figure 4a ). These data suggested that the three proteins indeed formed a complex. Immunoprecipitate with an anti-DUSP6 antibody confirms the binding of ERK 1/2 and BAG3, however, Hsp70 a well-known binding partner of BAG3 is not part of this complex, thus excluding a direct role for this protein in this process (Figure 4d ). Immuno-gold analysis confirms that the three proteins co-localize in the cytosol of HUVECs (Figure 4c ). To establish whether BAG3 is required for DUSP6 interaction with phospho-ERK1/2, we immunoprecipitated DUSP6 from extracts of control, NTsiRNA-or bag3siRNA-transfected cells and analysed the immunoprecipitate with anti-phospho-ERK1/2 antibody. As shown in Figure 4c , BAG3 silencing produced a reduction of the amount of phospho-ERK that can be co-immunoprecipited with DUSP6. Overexpression of DUSP6 in cells in which BAG3 is silenced does not affect the cell cycle thus confirming that in the absence of BAG3, DUSP6 fails to interact with ERK1/2 (data not shown). These findings indicate that BAG3 complexes with DUSP6 and phospho-ERK1/2 and is required for DUSP6 binding to phospho-ERK1/2, reducing BAG3 levels results in reduced binding between ERK1/2 and its phosphatase and therefore in increased levels of phospho-ERK1/2.
DISCUSSION
We and others have previously shown that increased constitutive expression of BAG3 in tumour cells contributes to tumour progression mostly through protection from cell death. Indeed we recently demonstrated that, in melanoma and osteosarcoma cells, BAG3 binding to Hsp70 interferes with the chaperonmediated delivery of the regulatory component of IKK complex, IKKg, to proteasome; this enhances NF-kB activation and sustains cell survival. In general, BAG3 is thought to impair the Hsp70-mediated delivery of anti-apoptotic proteins to proteasome, thereby increasing their intracellular levels and inhibiting apoptosis. 19 Here we show that BAG3 has an important role also in angiogenesis and that reducing BAG3 levels will result in reduced tumour growth also as a consequence of reduced angiogenesis. We also determine the molecular mechanism underlying BAG3 role in cell-cycle control of endothelial cells. HUVECs are targeted by a number of growth factors (VEGF, R3-IGF-1, hEGF and others) that induce, through their specific receptors, ERK phosphorylation. 39 --40 The phosphorylated kinase produces the activation of downstream targets, such as cyclin D1 resulting in progression from G1 to S. However, it is well known that sustained ERK phosphorylation results in a G1 block because of induced expression of Cdk inhibitors such as p21 and p15 (INK4b). This system allows a tight control of proliferation through regulation of ERK phosphorylation. An essential role in controlling ERK phosphorylation levels is played by DUSP phosphatases that allow cell-cycle progression reducing ERK phosphorylation. This mechanism is essential in the angiogenic process, where endothelial cells have to proliferate at high rates to form new vessels. We now demonstrate that BAG3 has an essential role in this mechanism. Indeed we show that BAG3 is required for DUSP6-ERK interaction that in turn assures that ERK phosphorylation does not reach levels leading to p21 and p15 expression and cell-cycle arrest.
Reduction of BAG3 results, as shown, in sustained ERK phosphorylation and reduced growth of endothelial cells both in vitro and in vivo. This constitutes an important proof of principle supporting the idea of anti-BAG3 therapies for tumour treatment by acting both directly on the tumour cells and on their vascular support.
In addition to the reported role in regulation of growth of endothelial cells this might be a more general regulation mechanism through which BAG3 regulates cell cycle in response BAG3 controls angiogenesis A Falco et al to different stimuli. A role for BAG1 in the regulation of the ERK signalling pathway has been previously reported where BAG1 bound and activated Raf-1, high levels of Hsp70 counteracted this interaction and repressed the signalling in response to heat shock. 41 This would be an additional mechanism through which the BAG family can regulate the ERK signalling pathway, downstream of the action reported for BAG1. Additional work is required to investigate if this regulatory mechanism is active in other cell models and if it is affected by the activation of the heatshock response. Indeed, although Hsp70 is not part of this complex it is entirely possible that it can regulate its formation by sequestering BAG3.
In conclusion we identified a novel molecular mechanism through which BAG3 exerts a previously unknown regulatory activity on the cell cycle by allowing the interaction between ERK and its phosphatase DUSP6, we also show that in principle this finding can be exploited to design novel anti-angiogenic therapies.
MATERIALS AND METHODS
Cells and culture conditions
HUVECs were purchased from Promocell (Heidelberg, Germany). All experiments were performed on low-passage cell cultures. Cells were grown in endothelial growth medium-2 (EBM-2, FBS 2%, VEGF, R 
Transfections
HUVECs were transfected with a specific si RNA targeting bag3 mRNA (5 0 -AAGGUUCAGACCAUCUUGGAA-3 0 ) or a NTsiRNA (5 0 -CAGUCGCGUUUGC GACUGG-3 0 ). For cell transfection, B6.5 Â 10 3 cells/cm 2 were plated in sixwell plates or in 100 mm petri dishes, in endothelial growth medium-2 media containing 2% foetal bovine serum and growth factors, to give 30 --40% confluence. Cells were transfected with a final siRNA concentration of 100 nM using Transfectin (Bio-Rad Laboratories, Inc., Hercules CA, USA). Transfection efficiency was evaluated in each experiment by western blot analysis.
Western blot analysis
Cells were harvested and lysed in a buffer containing 20 mM HEPES (pH 7.5), 150 mM NaCl, 0.1% Triton (TNN buffer) supplemented with protease inhibitors cocktail (1 mM phenylmethylsulfonyl fluoride, 1 mg/ml pepstatin A, 2 mg/ml aprotinin) by three cycles of freezing and thawing. Soluble proteins were collected and stored at À80 1C after a centrifugation at 10 000 g for 15 min. Protein amount was determined by Bradford assay (Bio-Rad) and 25 mg of total protein were run on 10 or 15% SDS --PAGE gels and electrophoretically transferred to nitrocellulose membrane. Nitrocellulose blots were blocked with 10% non-fat dry milk in TBST buffer (20 mM Tris--HCl pH 7.4, 500 mM NaCl and 0.1% Tween 20) and incubated with primary antibodies in TBST containing 5% bovine serum albumin or 5% non-fat dry milk, overnight at 4 1C. Immunoreactivity was detected by sequential incubation with horseradish peroxidase-conjugated secondary antibodies purchased from Pierce (Rockford, IL, USA) and ECL detection reagents purchased from Amersham Life Sciences Inc. (Arlington Heights, IL, USA).
Scanning densitometry of the bands was performed with an Image Scan (SnapScan 1212; Agfa-Gevaert NV, Mortsel, Belgium). The area under the curve related to each band was determined using Gimp2 software (http:// www.gimp.org). Background was subtracted from the calculated values.
Cell viability and cell-cycle analysis
Cells were synchronized by holding at confluence for 2 days, which arrests the cells in G0/G1 phase of the cell cycle. 21 Synchronized cells were plated at a cell density of 6.5 Â 10 3 cells/cm 2 and after 2 h were transfected with a specific bag3siRNA or a NTsiRNA. Cell viability was measured by trypan blue exclusion by a Burker chamber. Cell-cycle analysis was performed after incubation of cells with PI solution (2.5 mg/ml propidium iodide, 0.75 M sodium citrate pH 8.0, 0.1% Triton). Fluorescence intensity was measured by flow cytometry (FACScan Becton Dickinson, BD, Franklin Lakes, NJ, USA). For each sample, 10 000 events were recorded and histograms of red fluorescence versus counts were generated to evaluate percentages of cells in each phase of the cell cycle. The proportion of cells in each phase was calculated using ModFit LT software (BD).
Co-immunoprecipitation 100 ml of Affi-Gel 10 (Bio-Rad) were washed with cold deionized water, mixed with 7 mg of the antibody in 50 ml of coupling buffer (10 mM HEPES pH 7.5) and incubated for 1 h at room temperature. At the end of the reaction, the gel was extensively washed with phosphate-buffered saline (PBS). The unsaturated sites were blocked by adding 1 M ethanolamine (pH 8) 1/10 in respect to gel volume for 1 h at room temperature. The excess of ethanolamine was discarded by additional washes with PBS. Cells were harvested and lysed with TNN buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 0.1% Triton and 10% glycerol); 300 mg of proteins were incubated at 4 1C for 2 h with 30 ml of the antibody-affinity gel. Immunocomplexes were precipitated and washed five times with TNN buffer. Proteins obtained from immunoprecipitations and 20 mg of total proteins were loaded in a SDS --PAGE and blotted on a nitrocellulose membrane.
Immunoelectron microscopy Cells were sequentially dehydrated in ascending alcohols and infiltrated for 4 h at room temperature with three changes of LR white acrylic resin hard (Sigma, St Louis, MO, USA). Coverslips were covered with a cylindrical capsule filled with fresh LR white resin and polymerized at 60 1C for 24 h. Thin sections were collected on 400-mesh nickel grids, incubated for 30 min at room temperature in TBS blocking buffer (20 mM Tris--HCl, pH 7.6, 225 mM NaCl and 1% bovine serum albumin) containing 5% normal goat serum and then incubated overnight at 4 1C with a polyclonal antibody recognizing DUSP-6 (4 ng/ml). After this first step samples were fixed in glutaraldehyde 0.2% in PBS for 1 min. After 3 min washing in PBS, samples were incubated, on the other side, with the second (anti-ERK1/2, 4 ng/ml) and the third (AC-1, 8 ng/ml) primary monoclonal antibodies. After 10 min washing in TBS blocking buffer, samples were incubated for 1 h at room temperature with EM rabbit anti-goat IgG 10 nm gold (to detect DUSP-6), EM goat anti-rabbit IgG 20 nm gold (to detect ERK 1/2) and EM goat antimouse IgG 30 nm gold (to detect BAG3). Control grids were also included in which the primary antibody was omitted. Sections were stained with uranyl acetate and examined using a JEOL 100S electron microscope (JEOL, Peabody, MA, USA) operating at 80 kV.
Indirect immunofluorescence
Cells were cultured on coverslips in six-well plates to 60 --70% confluence and transfected with 100 nM bag3siRNA or NTsiRNA. After 36 h of transfection, coverslips were washed in 1 Â PBS and fixed in 3.7% formaldehyde in PBS 1 Â for 30 min at room temperature, and then incubated for 5 min with PBS 1 Â 0.1 M glycine. After washing, coverslips were permeabilized with 0.1% Triton X-100 for 5 min, washed again and incubated with blocking solution (5% normal goat serum in PBS 1 Â ) for 1 h at room temperature. Following incubation with a 1:100 dilution of anti-p15 INK4b polyclonal antibody and 3 mg/ml of anti-BAG3 mouse monoclonal antibody AC-1 at 4 1C, coverslips were washed three times with 1 Â PBS. After incubation with a 1 : 500 dilution of goat anti-mouse IgG DyLigth 488-conjugated antibodies (Jackson ImmunoResearch, West Grove, PA, USA) and a 1 : 500 dilution of goat anti-rabbit IgG DyLigth 649-conjugated antibodies (Jackson ImmunoResearch) at room temperature for 45 min, coverslips were again washed for three times in PBS and then in distilled water. The coverslips were then mounted on a slide with interspaces containing 47% (v/v) glycerol. Samples were analysed using a confocal laser scanning microscope (Leica SP5, Leica Microsystems, Wetzlar, Germany). Images were acquired in sequential scan mode by using the same acquisitions parameters (laser intensities, gain photomultipliers, pinhole aperture, objective 63 Â , zoom 2) when comparing experimental and control material. For production of figures, brightness and contrast of images were adjusted by taking care to leave a light cellular fluorescence background for visual appreciation of the lowest fluorescence intensity features and to help comparison among the different experimental groups. Final figures were assembled using Adobe Photoshop 7 and Adobe Illustrator 10 (Adobe systems incorporated, San Jose, CA, USA). Leica Confocal Software and ImageJ (Leica Microsystems, Wetzlar, Germany) were used for data analysis.
In vivo angiogenesis assay (Direct In Vivo Angiogenesis Assay)
In Vivo Angiogenesis Assay 26 --28 was performed by using Directed in Vivo Angiogenesis Assay (Cultrex, Trevigen, Inc. Helgerman Ct., Gaithersburg, MD, USA). Sterile silicone cylinders closed at one end (angioreactors) were filled with 20 ml of basement membrane extract premixed with angiogenesis factors (VEGF and FGF) or PBS. Furthermore bag3siRNA-Ad or AdNull BAG3 controls angiogenesis A Falco et al (10 8 pfu/100 ml) were added to angioreactors. These were incubated at 37 1C for 1 h to allow gel formation, before subcutaneous implantation into the dorsal flank of female BALB/c nu/nu mice (Charles River Laboratories, Wilmington, MA, USA). Animals were anaesthetized with 100 mg/ml ketamine HCL and 20 mg/ml xylazine injected subcutaneously. Incisions were made on the dorsal flank (left and right) of mouse, B1 cm above the hip-socket; angioreactors were implanted and incisions were closed with skin staple. Vessel formation evaluation was performed after 21 days. Matrigel was removed from angioreactors and digested in 300 ml of CellSperse solution for 1 h at 37 1C. After digestion, the incubation mix was cleared by centrifugation at 250 g. Cell pellets were resuspended in 500 ml of DMEM supplemented with 10% FBS and plated on glass slides in 24-wells plates for 16 h at 37 1C in 5% CO 2 . Cells were fixed with a 3.7% formaldehyde solution for 30 min at room temperature and quenched by incubation with 0.1 mM glycin for 5 min. Subsequently, cells were incubated with FITC-lectin reagent (available in the kit) and then observed by a fluorescence microscope (ZEISS, Gottingen, Germany). Number of FITC-lectin-positive cells were counted in 20 different fields for each samples.
Tumour growth analysis A375 xenografts were produced on the back of 6-week-old female BALB/c nu/nu mice (Charles River Laboratories) by subcutaneous injection of 5 Â 10 6 A375 cells in 500 ml of Hanks balanced salt solution. After 2 weeks of tumour cells injection, mice started the treatment with an adenovirus carrying a short hairpin RNA able to down-modulate BAG3 levels (bag3siRNA-Ad) or with a AdNull as previously described. 19 Mice with similar tumour sizes were randomized into three groups (10 mice per group) and treated with control PBS (100 ml), bag3siRNA-Ad or AdNull (10 8 pfu/100 ml), via intratumoral injection, twice a week. Tumour sizes were measured twice a week by a caliper and tumour volume was calculated as length Â width 2 Â 0.52. Mice with tumours of 41.5 cm in diameter was euthanized.
Immunohistochemistry
Tumours excised after 2 weeks treatments and formalin fixed, were included in paraffin blocks and sectioned at 6-mm thickness. Double immunohistochemical staining was performed using the EnVision G2 Doublestain System (peroxidase/alkaline-phosphatase-based visualization system) according to the manufacturer's instructions (Dako Denmark A/S, Glostrup, DK). Our modified protocol included deparaffination in xylene, rehydration through descending degrees of alcohol up to water, nonenzymatic antigen retrieval in citrate buffer, pH 6.0, for 30 min at 95 1C, and endogenous peroxidase quenching with H 2 O 2 in methanol for 20 min. After rinsing with TRIS buffer, the samples were blocked with 5% normal horse serum in TRIS buffer. Sections were incubated for 1 h at room temperature with primary antibodies diluted as follows: AC-1 1 : 300, p-ERK 1 : 750, p-21 1 : 50, HMB-45 1 : 50. Finally sections were counterstained with haematoxylin and mounted with permount.
Vascular density analysis
Immunohistochemical detection of vessels was performed with anti-von willebrand factor antibody (DAKO A/S). Vessels were counted in 10 fields of every tumour section and referred as the average number of blood vessels/field, with a light microscope.
Statistical analysis
Results are expressed as means±s.d. or ±s.e. Data were analysed by Student's t-test using Graph-Pad Prism statistical software version 4.01 (La Jolla, CA, USA). P-values from 0.01 to 0.05, from 0.001 to 0.01 or o0.001 were considered significant (*), very significant (**) or highly significant (***), respectively.
